BIALA, Grazyna, Ewa KEDZIERSKA, Marta KRUK-SLOMKA, Jolanta ORZELSKA-GORKA, Sara HMAIDAN, Aleksandra SKROK, Jakub KAMINSKI, Eva HAVRÁNKOVÁ, Dominika NADASKA a Ivan MALIK. Research in the Field of Drug Design and Development. Pharmaceuticals. BASEL: MDPI, 2023, roč. 16, č. 9, s. 1-23. ISSN 1424-8247. Dostupné z: https://dx.doi.org/10.3390/ph16091283.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Research in the Field of Drug Design and Development
Autoři BIALA, Grazyna (garant), Ewa KEDZIERSKA, Marta KRUK-SLOMKA, Jolanta ORZELSKA-GORKA, Sara HMAIDAN, Aleksandra SKROK, Jakub KAMINSKI, Eva HAVRÁNKOVÁ (203 Česká republika, domácí), Dominika NADASKA a Ivan MALIK.
Vydání Pharmaceuticals, BASEL, MDPI, 2023, 1424-8247.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30104 Pharmacology and pharmacy
Stát vydavatele Švýcarsko
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 4.600 v roce 2022
Kód RIV RIV/00216224:14160/23:00132055
Organizační jednotka Farmaceutická fakulta
Doi http://dx.doi.org/10.3390/ph16091283
UT WoS 001074283700001
Klíčová slova anglicky drug discovery; drug synthesis; in vivo studies; in vitro studies; clinical trials
Štítky rivok, ÚChL
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: JUDr. Sabina Krejčiříková, učo 383857. Změněno: 27. 10. 2023 15:29.
Anotace
The processes used by academic and industrial scientists to discover new drugs have recently experienced a true renaissance, with many new and exciting techniques being developed over the past 5-10 years alone. Drug design and discovery, and the search for new safe and well-tolerated compounds, as well as the ineffectiveness of existing therapies, and society's insufficient knowledge concerning the prophylactics and pharmacotherapy of the most common diseases today, comprise a serious challenge. This can influence not only the quality of human life, but also the health of whole societies, which became evident during the COVID-19 pandemic. In general, the process of drug development consists of three main stages: drug discovery, preclinical development using cell-based and animal models/tests, clinical trials on humans and, finally, forward moving toward the step of obtaining regulatory approval, in order to market the potential drug. In this review, we will attempt to outline the first three most important consecutive phases in drug design and development, based on the experience of three cooperating and complementary academic centers of the Visegrad group; i.e., Medical University of Lublin, Poland, Masaryk University of Brno, Czech Republic, and Comenius University Bratislava, Slovak Republic.
VytisknoutZobrazeno: 17. 7. 2024 07:22